PDF(Pubmed)
Abstract：
UNASSIGNED: Although adalimumab is the only approved biologic for the treatment of hidradenitis suppurativa (HS), the treatment response may not be satisfactory in all patients. Recently, many other biological agents, including interleukin 17 inhibitors such as ixekizumab, have shown promise.
UNASSIGNED: Five severe HS (Hurley stage III) patients resistant to conventional treatments and adalimumab for at least 3 months were recruited. Patients were prescribed ixekizumab with a scheme approved for psoriasis (160 mg once, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12.) The primary outcome measure was achieving the Hidradenitis Suppurativa Clinical Response (HiSCR) score following 12 weeks. Secondary outcome measures included the patient-reported Dermatology Life Quality Index (DLQI) and visual analog scale (VAS). Four of 5 patients (80%) achieved HiSCR. While improvement was observed in the VAS and DLQI scores of 4 patients, the decline was limited in 1 patient. No adverse event was recorded related to ixekizumab.
UNASSIGNED: The result of our observation suggests that ixekizumab may be effective for HS, especially in challenging cases.
UNASSIGNED: Five severe HS (Hurley stage III) patients resistant to conventional treatments and adalimumab for at least 3 months were recruited. Patients were prescribed ixekizumab with a scheme approved for psoriasis (160 mg once, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12.) The primary outcome measure was achieving the Hidradenitis Suppurativa Clinical Response (HiSCR) score following 12 weeks. Secondary outcome measures included the patient-reported Dermatology Life Quality Index (DLQI) and visual analog scale (VAS). Four of 5 patients (80%) achieved HiSCR. While improvement was observed in the VAS and DLQI scores of 4 patients, the decline was limited in 1 patient. No adverse event was recorded related to ixekizumab.
UNASSIGNED: The result of our observation suggests that ixekizumab may be effective for HS, especially in challenging cases.
摘要：
■尽管阿达木单抗是唯一被批准用于治疗化脓性汗腺炎（HS）的生物制剂，治疗反应可能并非所有患者都令人满意.最近,许多其他生物制剂，包括白介素17抑制剂，如ixekizumab，显示出了希望。
■招募了5名对常规治疗和阿达木单抗耐药至少3个月的重度HS（HurleyIII期）患者。患者服用ixekizumab，并采用批准用于牛皮癣的方案（160毫克一次，然后在第2、4、6、8、10和12周服用80mg。）主要结果指标是在12周后达到化脓性汗腺炎临床反应（HiSCR）评分。次要结果指标包括患者报告的皮肤病学生活质量指数（DLQI）和视觉模拟量表（VAS）。5例患者中有4例（80％）实现了HiSCR。虽然4例患者的VAS和DLQI评分有所改善，1例患者的下降幅度有限.没有记录到与ixekizumab相关的不良事件。
■我们的观察结果表明，ixekizumab可能对HS有效，尤其是在具有挑战性的情况下。
■招募了5名对常规治疗和阿达木单抗耐药至少3个月的重度HS（HurleyIII期）患者。患者服用ixekizumab，并采用批准用于牛皮癣的方案（160毫克一次，然后在第2、4、6、8、10和12周服用80mg。）主要结果指标是在12周后达到化脓性汗腺炎临床反应（HiSCR）评分。次要结果指标包括患者报告的皮肤病学生活质量指数（DLQI）和视觉模拟量表（VAS）。5例患者中有4例（80％）实现了HiSCR。虽然4例患者的VAS和DLQI评分有所改善，1例患者的下降幅度有限.没有记录到与ixekizumab相关的不良事件。
■我们的观察结果表明，ixekizumab可能对HS有效，尤其是在具有挑战性的情况下。
